vTv Therapeutics is a biopharmaceutical company that develops orally administered therapies targeting metabolic and inflammatory diseases, primarily diabetes. Its lead program, cadisegliatin, is a liver-selective glucokinase activator in advanced clinical development as an adjunctive therapy to insulin for type 1 diabetes, supported by evidence of hypoglycemia reduction and HbA1c improvements. The company's pipeline includes other oral small-molecule candidates such as a GLP-1 receptor agonist and various modulators for metabolic and inflammatory indications, while also licensing assets to partners in exchange for upfront payments, milestone fees, and royalties on future sales. vTv targets the large and growing population of diabetes patients, particularly those with significant unmet medical needs around hypoglycemia management and glycemic control.